Accordingly, this review ends with a discussion of the status and therapeutic potential of glucagon receptor antagonists, -cell selective somatostatin agonists, glucagon-like peptide-1 agonists, and dipeptidyl peptidase-IV inhibitors.

• 因此,文章结尾讨论了胰高糖素受体拮抗剂、细胞选择性生长抑素激动剂、胰高糖素样肽-1激动剂和二肽酶-IV抑制剂的情况及其治疗潜能。